JP2001516221A - 哺乳類細胞内の特定部位に相同組換えによって遺伝子を組み込む方法とそれを実施するためのベクター - Google Patents
哺乳類細胞内の特定部位に相同組換えによって遺伝子を組み込む方法とそれを実施するためのベクターInfo
- Publication number
- JP2001516221A JP2001516221A JP54053998A JP54053998A JP2001516221A JP 2001516221 A JP2001516221 A JP 2001516221A JP 54053998 A JP54053998 A JP 54053998A JP 54053998 A JP54053998 A JP 54053998A JP 2001516221 A JP2001516221 A JP 2001516221A
- Authority
- JP
- Japan
- Prior art keywords
- dna
- plasmid
- marker
- cells
- selectable marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳類細胞のゲノム中の標的部位に所望のDNAを挿入する方法であって、 次の各段階を含む方法: (i)哺乳類細胞を次の各配列を含む第一プラスミド(「マーカープラスミド」 )でトランスフェクション又は形質転換し: (a)哺乳類細胞ゲノムに組み込まれた時に相同組換え用のユニーク部位を提 供する、哺乳類細胞ゲノムに対して非相同的なDNAの領域; (b)第一選択可能マーカータンパク質の一部をコードするDNA断片;及び (c)マーカープラスミドがうまく組み込まれている哺乳類細胞の選択に備え た少なくとも一つの他の選択可能マーカーDNA; (ii)そのゲノムに組込まれたマーカープラスミドを含有する細胞を選択し; (iii)選択したその細胞を次の各配列を含む第二プラスミド(「ターゲットプ ラスミド」)でトランスフェクション又は形質転換し: (a)マーカープラスミド中のユニーク領域と同一であるか、若しくはそのDNA の領域が相同組換えにより該DNAと組換えを起こしうるほど十分に相同であるDNA の領域; (b)マーカープラスミドに含まれるものと同じ選択可能マーカーの一部をコ ードするDNA断片(ここに、該DNAによってコードされる活性な選択可能マーカー タンパク質は、該断片がマーカープラスミドに含まれる該選択可能マーカーDNA の断片と共同して発現される場合にのみ産生される); (iv)第一選択可能マーカータンパク質の発現についてスクリーニングすること により、標的部位に組み込まれたターゲットプラスミドを含有する細胞を選択す る。 2.第一選択可能マーカーの断片をコードするDNA断片が優性選択可能マーカ ーの1つのエクソンである請求の範囲1に記載の方法。 3.第二プラスミドが該第一選択可能マーカーの残りのエクソンを含有する請 求の範囲2に記載の方法。 4.所望のタンパク質をコードする少なくとも一つのDNAが、ターゲットプラ スミドに含まれる該第一選択可能マーカーの該エクソン間に挿入される請求の範 囲3に記載の方法。 5.所望のタンパク質をコードするDNAの同時増幅に備えるために、優性選択 可能マーカーをコードするDNAが、更に、ターゲットプラスミドに含まれる該第 一選択可能マーカーのエクソン間に挿入される請求の範囲4に記載の方法。 6.第一優性選択可能マーカーがネオマイシンホスホトランスフェラーゼ、ヒ スチジノールデヒドロゲナーゼ、ジヒドロ葉酸レダクターゼ、ハイグロマイシン ホスホトランスフェラーゼ、単純ヘルペスウイルスチミジンキナーゼ、アデノシ ンデアミナーゼ、グルタミンシンテターゼ及びヒポキサンチン-グアニンホスホ リボシルトランスフェラーゼからなる群より選択される請求の範囲3に記載の方 法。 7.所望のタンパク質が哺乳類タンパク質である請求の範囲4に記載の方法。 8.そのタンパク質が免疫グロブリンである請求の範囲7に記載の方法。 9.マーカープラスミドに含まれる選択マーカー(c)のRNAレベルを、ターゲ ットベクターの組込みに先立って決定する段階を更に含む請求の範囲1に記載の 方法。 10.マーカープラスミドに含まれる当該他の選択可能マーカーがヒスチジノー ルデヒドロゲナーゼ、単純ヘルペスチミジンキナーゼ、ハイドロマイシンホスホ トランスフェラーゼ、アデノシンデアミナーゼ及びグルタミンシンテターゼから なる群より選択される請求の範囲9に記載の方法。 11.哺乳類細胞がチャイニーズハムスター卵巣(CHO)細胞、骨髄腫細胞、ベ ビーハムスター腎細胞、COS細胞、NSO細胞、HeLa細胞及びNIH 3T3細胞からなる 群より選択される請求の範囲1に記載の方法。 12.その細胞がCHO細胞である請求の範囲11に記載の方法。 13.マーカープラスミドがネオマイシンホスホトランスフェラーゼ遺伝子の第 三エクソンを含有し、ターゲットプラスミドがネオマイシンホスホトランスフェ ラーゼ遺伝子の最初の2つのエクソンを含有する請求の範囲1に記載の方法。 14.マーカープラスミドが更に、相同領域内に挿入された珍しい制限エンドヌ クレアーゼ配列を含有する請求の範囲1に記載の方法。 15.相同組換えに備えたDNAのユニーク領域が細菌DNA、ウイルスDNA又は合成D NAである請求の範囲1に記載の方法。 16.相同組換えに備えたDNAのユニーク領域が少なくとも300ヌクレオチドであ る請求の範囲1に記載の方法。 17.DNAのユニーク領域のサイズが約300ヌクレオチドから20キロ塩基までの範 囲にある請求の範囲16に記載の方法。 18.DNAのユニーク領域のサイズが2〜10キロ塩基の範囲にある請求の範囲17に 記載の方法。 19.第一選択可能マーカーDNAが少なくとも3つのエクソンに分割される請求の 範囲1に記載の方法。 20.相同組換えに備えたDNAのユニーク領域が細菌DNA、昆虫DNA、ウイルスDNA 又は合成DNAである請求の範囲1に記載の方法。 21.DNAのユニーク領域が機能的な遺伝子を含有しない請求の範囲20に記載の 方法。 22.哺乳類細胞のゲノム中の標的部位に所望のDNAを挿入するためのベクター 系であって、少なくとも下記を含んでなるもの: (i)少なくとも次の各配列を含む第一プラスミド(「マーカープラスミド」) : (a)哺乳類細胞ゲノムに組み込まれた時に相同組換え用のユニーク部位を提 供する、哺乳類細胞ゲノムに対して非相同的なDNAの領域; (b)第一選択可能マーカータンパク質の一部をコードするDNA断片;及び (c)マーカープラスミドがうまく組み込まれている哺乳類細胞の選択に備え た少なくとも一つの他の選択可能マーカーDNA; (ii)少なくとも次の各配列を含む第二プラスミド(「ターゲットプラスミド」 ): (a)マーカープラスミド中のユニーク領域と同一であるか、若しくはそのDNA の領域が相同組換えにより該DNAと組換えを起こしうるほど十分に相同であるDNA の領域; (b)マーカープラスミドに含まれるものと同じ選択可能マーカーの一部をコ ードするDNA断片(ここに、該DNAによってコードされる活性な選択可能マーカー タンパク質は、該断片がマーカープラスミドに含まれる該選択可能マーカーDNA の断片と共同して発現される場合にのみ産生される)。 23.第一選択可能マーカーの断片をコードするDNA断片が優性選択可能マーカ ーの1つのエクソンである請求の範囲22に記載のベクター系。 24.第二プラスミドが該第一選択可能マーカーの残りのエクソンを含有する請 求の範囲23に記載のベクター系。 25.所望のタンパク質をコードする少なくとも一つのDNAが、ターゲットプラ スミドに含まれる該第一選択可能マーカーの該エクソン間に挿入される請求の範 囲24に記載のベクター系。 26.所望のタンパク質をコードするDNAの同時増幅に備えるために、優性選択 可能マーカーをコードするDNAが、更に、ターゲットプラスミドに含まれる該第 一選択可能マーカーのエクソン問に挿入される請求の範囲24に記載のベクター系 。 27.第一優性選択可能マーカーがネオマイシンホスホトランスフェラーゼ、ヒ スチジノールデヒドロゲナーゼ、ジヒドロ葉酸レダクターゼ、ハイグロマイシン ホスホトランスフェラーゼ、単純ヘルペスウイルスチミジンキナーゼ、アデノシ ンデアミナーゼ、グルタミンシンテターゼ及びヒポキサンチン-グアニンホスホ リボシルトランスフェラーゼからなる群より選択される請求の範囲24に記載のベ クター系。 28.所望のタンパク質が哺乳類タンパク質である請求の範囲25に記載のベクタ ー系。 29.そのタンパク質が免疫グロブリンである請求の範囲28に記載のベクター系 。 30.マーカープラスミドに含まれる当該他の選択可能マーカーがヒスチジノー ルデヒドロゲナーゼ、単純ヘルペスチミジンキナーゼ、ハイドロマイシンホスホ トランスフェラーゼ、アデノシンデアミナーゼ及びグルタミンシンテターゼから なる群より選択される請求の範囲22に記載のベクター系。 31.チャイニーズハムスター卵巣(CHO)細胞、骨髄腫細胞、ベビーハムスタ ー腎細胞、COS細胞、NSO細胞、HeLa細胞及びNH 3T3細胞からなる群より選択され る哺乳類細胞のゲノム中の標的部位に所望のDNAを導入するための請求の範囲 22に記載のベクター系。 32.その哺乳類細胞がCHO細胞である請求の範囲31に記載のベクター系。 33.マーカープラスミドがネオマイシンホスホトランスフェラーゼ遺伝子の第 三エクソンを含有し、ターゲットプラスミドがネオマイシンホスホトランスフェ ラーゼ遺伝子の最初の2つのエクソンを含有する請求の範囲22に記載のベクター 系。 34.マーカープラスミドが更に、相同領域内に挿入された珍しい制限エンドヌ クレアーゼ配列を含有する請求の範囲22に記載のベクター系。 35.相同組換えに備えたDNAのユニーク領域が細菌DNA、ウイルスDNA又は合成D NAである請求の範囲22に記載のベクター系。 36.相同組換えに備えたマーカープラスミドベクター系に含まれるDNA(a)の ユニーク領域が少なくとも300ヌクレオチドである請求の範囲22に記載のベクタ ー系。 37.DNAのユニーク領域のサイズが約300ヌクレオチドから20キロ塩基までの範 囲にある請求の範囲36に記載のベクター系。 38.DNAのユニーク領域のサイズが2〜10キロ塩基の範囲にある請求の範囲37に 記載のベクター系。 39.第一選択可能マーカーDNAが少なくとも3つのエクソンに分割される請求の 範囲22に記載のベクター系。 40.相同組換えに備えたDNAのユニーク領域が細菌DNA、昆虫DNA、ウイルスDNA 又は合成DNAである請求の範囲22に記載のベクター系。 41.DNAのユニーク領域が機能的な遺伝子を含有しない請求の範囲40に記載の ベクター系。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/819,866 US5830698A (en) | 1997-03-14 | 1997-03-14 | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US08/819,866 | 1997-03-14 | ||
US09/023,715 US5998144A (en) | 1997-03-14 | 1998-02-13 | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US09/023,715 | 1998-02-13 | ||
PCT/US1998/003935 WO1998041645A1 (en) | 1997-03-14 | 1998-03-09 | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001516221A true JP2001516221A (ja) | 2001-09-25 |
JP2001516221A5 JP2001516221A5 (ja) | 2005-11-10 |
JP4128227B2 JP4128227B2 (ja) | 2008-07-30 |
Family
ID=26697516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54053998A Expired - Fee Related JP4128227B2 (ja) | 1997-03-14 | 1998-03-09 | 哺乳類細胞内の特定部位に相同組換えによって遺伝子を組み込む方法とそれを実施するためのベクター |
Country Status (21)
Country | Link |
---|---|
US (3) | US6413777B1 (ja) |
EP (1) | EP0981637B1 (ja) |
JP (1) | JP4128227B2 (ja) |
CN (1) | CN1175111C (ja) |
AT (1) | ATE296356T1 (ja) |
AU (1) | AU737155B2 (ja) |
BR (1) | BR9808584A (ja) |
CA (1) | CA2283740C (ja) |
CZ (1) | CZ293355B6 (ja) |
DE (1) | DE69830312T2 (ja) |
ES (1) | ES2242997T3 (ja) |
ID (1) | ID24565A (ja) |
IL (1) | IL131746A0 (ja) |
IN (1) | IN189732B (ja) |
NO (1) | NO994397L (ja) |
PL (1) | PL191251B1 (ja) |
PT (1) | PT981637E (ja) |
RO (1) | RO120148B1 (ja) |
RU (1) | RU2004107694A (ja) |
TW (1) | TWI232239B (ja) |
WO (1) | WO1998041645A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008523793A (ja) * | 2004-12-15 | 2008-07-10 | ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ | B型リンパ球様造血増殖に対する細胞傷害性抗体 |
WO2011040285A1 (ja) | 2009-10-01 | 2011-04-07 | Toto株式会社 | Dna構築物およびそれを用いた組み換えcho細胞の製造方法 |
JP2011092196A (ja) * | 2010-12-10 | 2011-05-12 | Lonza Biologics Plc | Cho細胞において組換えタンパク質を発現する方法 |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
PT981637E (pt) * | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
DK1036198T3 (da) | 1997-12-08 | 2013-01-02 | California Inst Of Techn | Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser |
WO2000039304A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
GB9912965D0 (en) * | 1999-06-03 | 1999-08-04 | Oxford Biomedica Ltd | In vivo selection method |
AU2400500A (en) * | 1999-11-01 | 2001-05-14 | Chiron Corporation | Expression vectors, transfection systems, and method of use thereof |
DK1297170T3 (en) * | 2000-06-23 | 2016-03-14 | Novozymes As | A process for stable chromosomal integration of multiple copies of the genes |
AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
JP2005535282A (ja) | 2001-11-16 | 2005-11-24 | アイデック ファーマシューティカルズ コーポレイション | 抗体のポリシストロニック発現 |
US7164056B2 (en) * | 2002-05-03 | 2007-01-16 | Pioneer Hi-Bred International, Inc. | Gene targeting using replicating DNA molecules |
CN101537180B (zh) | 2002-07-18 | 2016-02-10 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
AU2003286684A1 (en) * | 2002-10-30 | 2004-06-07 | Gail Bishop | Somatic cell gene targeting vectors and methods of use thereof |
DE602004002275T2 (de) | 2003-01-07 | 2007-09-06 | Symphogen A/S | Verfahren zur herstellung rekombinanterpolyklonaler proteine |
DE10303937A1 (de) * | 2003-01-31 | 2004-08-12 | Icon Genetics Ag | Pflanzentransformation mit Assemblierung einer gewünschten Sequenz in Vivo |
AU2004207177B2 (en) * | 2003-01-31 | 2008-02-07 | Bayer Cropscience N.V. | Plant transformation with in vivo assembly of a trait |
PL378582A1 (pl) | 2003-03-19 | 2006-05-02 | Biogen Idec Ma Inc. | Białko wiążące receptor Nogo |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP1626993B1 (en) * | 2003-05-09 | 2015-03-11 | Duke University | Cd20-specific antibodies and methods of employing same |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
EP1641826A2 (en) * | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
CA2536807C (en) | 2003-09-04 | 2010-07-13 | Medarex, Inc. | Expression vector |
US7344753B2 (en) * | 2003-09-19 | 2008-03-18 | The Board Of Trustees Of The University Of Illinois | Nanostructures including a metal |
US8030833B2 (en) * | 2003-09-19 | 2011-10-04 | The Board Of Trustees Of The University Of Illinois | Electron emission device incorporating free standing monocrystalline nanowires |
US7935862B2 (en) * | 2003-12-02 | 2011-05-03 | Syngenta Participations Ag | Targeted integration and stacking of DNA through homologous recombination |
DK1737971T3 (da) | 2004-01-20 | 2017-11-13 | Merus Nv | Blandinger af bindingsproteiner |
AU2005258335B2 (en) | 2004-06-24 | 2011-03-17 | Biogen Ma Inc. | Treatment of conditions involving demyelination |
DK2053408T3 (da) | 2004-07-20 | 2012-06-04 | Symphogen As | Fremgangsmåde til strukturel karakterisering af et rekombinant polyklonalt protein eller en polyklonal cellelinje |
US7846438B2 (en) | 2004-08-03 | 2010-12-07 | Biogen Idec Ma Inc. | Methods of promoting neurite outgrowth with soluble TAJ polypeptides |
EP2311880A3 (en) | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
CN100381573C (zh) * | 2005-04-14 | 2008-04-16 | 北京天广实生物技术有限公司 | 快速构建目标基因高表达的哺乳动物细胞株的体系和方法 |
MX2008000253A (es) | 2005-07-08 | 2008-04-02 | Biogen Idec Inc | Anticuerpos de sp35 y usos de los mismos. |
EP3138403A1 (en) | 2005-08-09 | 2017-03-08 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
EP2510934A1 (en) | 2005-11-04 | 2012-10-17 | Biogen Idec MA Inc. | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
US20090175872A1 (en) | 2005-12-02 | 2009-07-09 | Biogen Idec Ma Inc. | Treatment of Conditions Involving Demyelination |
US20070136826A1 (en) * | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
ES2550099T3 (es) | 2006-01-27 | 2015-11-04 | Biogen Ma Inc. | Antagonistas del receptor Nogo |
DK2426143T3 (en) | 2007-01-05 | 2017-09-11 | Univ Zuerich | Process for providing disease-specific binding molecules and targets |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
PT2740744T (pt) | 2007-01-09 | 2018-06-06 | Biogen Ma Inc | Anticorpos sp35 e suas utilizações |
EP2114433B1 (en) | 2007-02-02 | 2014-04-09 | Biogen Idec MA Inc. | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
WO2009048605A1 (en) * | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
EP2217697B1 (en) * | 2007-11-08 | 2015-06-10 | Biogen MA Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
US20110119779A1 (en) * | 2007-12-10 | 2011-05-19 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
EP2315779A2 (en) * | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
US9346873B2 (en) | 2008-09-30 | 2016-05-24 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
ES2544569T3 (es) | 2008-12-19 | 2015-09-01 | Biogen International Neuroscience Gmbh | Autoanticuerpos humanos anti alfa-sinucleina |
EP2382238A1 (en) | 2008-12-31 | 2011-11-02 | Biogen Idec MA Inc. | Anti-lymphotoxin antibodies |
RU2542394C2 (ru) | 2009-03-24 | 2015-02-20 | ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. | Гуманизированные антитела против light и их применение |
EP4345163A2 (en) | 2010-03-31 | 2024-04-03 | Ablexis, LLC | Genetic engineering of non-human animals for the production of chimeric antibodies |
SG184903A1 (en) * | 2010-04-30 | 2012-11-29 | Temasek Life Sciences Lab Ltd | Fragment switch: a reverse genetic approach |
EP2591099B1 (en) | 2010-07-09 | 2020-11-18 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
PL2627672T3 (pl) | 2010-10-11 | 2018-11-30 | Biogen International Neuroscience Gmbh | Ludzkie przeciwciała anty-tau |
DK2640743T3 (en) | 2010-11-16 | 2017-01-23 | Excelimmune Inc | PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS |
US9283271B2 (en) | 2010-12-17 | 2016-03-15 | Neurimmune Holding Ag | Human anti-SOD1 antibodies |
DK2723379T3 (en) | 2011-06-23 | 2018-10-15 | Biogen Int Neuroscience Gmbh | ANTI-ALPHA SYNUCLEIN BINDING MOLECULES |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
US10233424B2 (en) | 2011-12-22 | 2019-03-19 | Elwha Llc | Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin |
US10745468B2 (en) | 2011-12-22 | 2020-08-18 | Kota Biotherapeutics, Llc | Compositions and methods for modified B cells expressing reassigned biological agents |
US9175072B2 (en) | 2011-12-22 | 2015-11-03 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen |
US8962315B2 (en) | 2011-12-22 | 2015-02-24 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen |
PT2838918T (pt) | 2012-04-20 | 2019-08-23 | Merus Nv | Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig |
SG11201406547YA (en) | 2012-04-25 | 2014-11-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
JP6559063B2 (ja) | 2012-05-07 | 2019-08-14 | サンガモ セラピューティクス, インコーポレイテッド | 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物 |
CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | CHIMERIC COAGULATION FACTORS |
EP2906240A2 (en) | 2012-10-09 | 2015-08-19 | Biogen MA Inc. | Combination therapies and uses for treatment of demyelinating disorders |
ES2816700T3 (es) | 2012-12-21 | 2021-04-05 | Biogen Ma Inc | Anticuerpos anti-tau humanos |
WO2014102399A1 (en) | 2012-12-31 | 2014-07-03 | Neurimmune Holding Ag | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
HRP20231183T1 (hr) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
EP3201228A2 (en) | 2014-09-30 | 2017-08-09 | Neurimmune Holding AG | Human-derived anti-dipeptide repeats (dprs) antibody |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Lingo‐1拮抗薬及び脱髄障害の治療のための使用 |
CN106191040B (zh) * | 2015-04-30 | 2021-09-14 | 杭州菁因康生物科技有限公司 | 基因打靶方法 |
MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
SI3411478T1 (sl) | 2016-02-01 | 2022-10-28 | Bioverativ Therapeutics Inc. | Optimirani geni dejavnika VIII |
WO2017214376A1 (en) | 2016-06-10 | 2017-12-14 | Elwha Llc | Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
AU2017297404A1 (en) | 2016-07-13 | 2019-01-24 | Biogen Ma Inc. | Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders |
BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
TW201831521A (zh) | 2017-01-31 | 2018-09-01 | 美商生物化學醫療公司 | 因子ix融合蛋白以及其製備方法及使用方法 |
MX2020009975A (es) | 2018-03-28 | 2020-10-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso. |
US20210238289A1 (en) | 2018-06-04 | 2021-08-05 | Biogen Ma Inc. | Anti-vla-4 antibodies having reduced effector function |
CN110607326B (zh) * | 2018-06-15 | 2022-11-29 | 江苏省农业科学院 | 非强启动式的外源基因表达法及其在具有毒性的目标蛋白表达中的应用 |
SG11202103111TA (en) * | 2018-10-01 | 2021-04-29 | Lonza Ag | Ssi cells with predictable and stable transgene expression and methods of formation |
KR20210126078A (ko) | 2019-02-13 | 2021-10-19 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 항-말초 림프절 어드레신 항체 및 그의 용도 |
WO2023028455A1 (en) | 2021-08-23 | 2023-03-02 | Bioverativ Therapeutics Inc. | Closed-end dna production with inverted terminal repeat sequences |
IL310997A (en) | 2021-08-23 | 2024-04-01 | Bioverativ Therapeutics Inc | Factor VIII gene optimization |
IL311725A (en) | 2021-09-30 | 2024-05-01 | Bioverativ Therapeutics Inc | Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
WO1991006666A1 (en) | 1989-11-06 | 1991-05-16 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
AU4401993A (en) * | 1992-06-04 | 1993-12-30 | Exemplar Corporation | Insertion of heterologous dna outside of known chromosomal genes |
MX9305183A (es) * | 1992-08-27 | 1994-05-31 | Us Agriculture | Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion. |
US5648267A (en) * | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
PT981637E (pt) | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
-
1998
- 1998-03-09 PT PT98910109T patent/PT981637E/pt unknown
- 1998-03-09 ES ES98910109T patent/ES2242997T3/es not_active Expired - Lifetime
- 1998-03-09 RO RO99-00972A patent/RO120148B1/ro unknown
- 1998-03-09 AU AU64435/98A patent/AU737155B2/en not_active Ceased
- 1998-03-09 CN CNB988049880A patent/CN1175111C/zh not_active Expired - Fee Related
- 1998-03-09 BR BR9808584-0A patent/BR9808584A/pt not_active Application Discontinuation
- 1998-03-09 CZ CZ19993162A patent/CZ293355B6/cs not_active IP Right Cessation
- 1998-03-09 CA CA002283740A patent/CA2283740C/en not_active Expired - Fee Related
- 1998-03-09 AT AT98910109T patent/ATE296356T1/de not_active IP Right Cessation
- 1998-03-09 DE DE69830312T patent/DE69830312T2/de not_active Revoked
- 1998-03-09 WO PCT/US1998/003935 patent/WO1998041645A1/en active IP Right Grant
- 1998-03-09 IL IL13174698A patent/IL131746A0/xx not_active IP Right Cessation
- 1998-03-09 JP JP54053998A patent/JP4128227B2/ja not_active Expired - Fee Related
- 1998-03-09 ID IDW991196A patent/ID24565A/id unknown
- 1998-03-09 EP EP98910109A patent/EP0981637B1/en not_active Revoked
- 1998-03-09 PL PL335695A patent/PL191251B1/pl not_active IP Right Cessation
- 1998-03-10 IN IN616DE1998 patent/IN189732B/en unknown
- 1998-03-13 TW TW087103778A patent/TWI232239B/zh not_active IP Right Cessation
-
1999
- 1999-06-30 US US09/343,485 patent/US6413777B1/en not_active Expired - Fee Related
- 1999-09-10 NO NO994397A patent/NO994397L/no not_active Application Discontinuation
-
2002
- 2002-04-01 US US10/109,853 patent/US6841383B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 RU RU2004107694/13A patent/RU2004107694A/ru not_active Application Discontinuation
- 2004-04-06 US US10/817,950 patent/US7235360B2/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008523793A (ja) * | 2004-12-15 | 2008-07-10 | ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ | B型リンパ球様造血増殖に対する細胞傷害性抗体 |
JP2012126724A (ja) * | 2004-12-15 | 2012-07-05 | Lfb Biotechnologies | B型リンパ球様造血増殖に対する細胞傷害性抗体 |
WO2011040285A1 (ja) | 2009-10-01 | 2011-04-07 | Toto株式会社 | Dna構築物およびそれを用いた組み換えcho細胞の製造方法 |
JP2011092196A (ja) * | 2010-12-10 | 2011-05-12 | Lonza Biologics Plc | Cho細胞において組換えタンパク質を発現する方法 |
Also Published As
Publication number | Publication date |
---|---|
CZ293355B6 (cs) | 2004-04-14 |
CN1255166A (zh) | 2000-05-31 |
NO994397D0 (no) | 1999-09-10 |
IN189732B (ja) | 2003-04-19 |
ID24565A (id) | 2000-07-27 |
BR9808584A (pt) | 2000-05-23 |
RU2004107694A (ru) | 2005-08-27 |
JP4128227B2 (ja) | 2008-07-30 |
PT981637E (pt) | 2005-09-30 |
CA2283740C (en) | 2006-06-27 |
PL335695A1 (en) | 2000-05-08 |
RO120148B1 (ro) | 2005-09-30 |
TWI232239B (en) | 2005-05-11 |
ATE296356T1 (de) | 2005-06-15 |
US20020192820A1 (en) | 2002-12-19 |
CN1175111C (zh) | 2004-11-10 |
EP0981637A1 (en) | 2000-03-01 |
PL191251B1 (pl) | 2006-04-28 |
NO994397L (no) | 1999-11-09 |
EP0981637B1 (en) | 2005-05-25 |
US7235360B2 (en) | 2007-06-26 |
CA2283740A1 (en) | 1998-09-24 |
DE69830312T2 (de) | 2006-02-02 |
US20040166528A1 (en) | 2004-08-26 |
WO1998041645A1 (en) | 1998-09-24 |
US6413777B1 (en) | 2002-07-02 |
ES2242997T3 (es) | 2005-11-16 |
IL131746A0 (en) | 2001-03-19 |
US6841383B2 (en) | 2005-01-11 |
DE69830312D1 (de) | 2005-06-30 |
AU6443598A (en) | 1998-10-12 |
AU737155B2 (en) | 2001-08-09 |
CZ316299A3 (cs) | 2000-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001516221A (ja) | 哺乳類細胞内の特定部位に相同組換えによって遺伝子を組み込む方法とそれを実施するためのベクター | |
US5998144A (en) | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same | |
WO1998041645A9 (en) | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same | |
Askew et al. | Site-directed point mutations in embryonic stem cells: a gene-targeting tag-and-exchange strategy | |
Baker et al. | Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over | |
US5998209A (en) | Generation of large genomic DNA deletions | |
SG173217A1 (en) | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions | |
EP0755402A1 (en) | Alpha(1,3) galactosyltransferase negative swine | |
JP2001186897A (ja) | 相同組換え法を用いてのタンパク質の生成 | |
JP2003510072A (ja) | 遺伝子発現を改変するための組成物および方法 | |
AU684275B2 (en) | Method for defined deletions of DNA | |
EP1474522B1 (en) | A method for generating engineered cells for locus specific gene regulation and analysis | |
MXPA99008363A (en) | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same | |
AU7933601A (en) | alpha(1,3)-galactosyltransferase negative swine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050301 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070828 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080310 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080415 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080514 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110523 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |